Navigation Links
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
Date:3/6/2009

options to improve lung function and control exacerbations.

About aclidinium bromide and Genuair(R)

Aclidinium bromide is a novel, long-acting inhaled anticholinergic bronchodilator which has a long residence time at the M3 receptors and a shorter residence time at the M2 receptors. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Forest Laboratories licensed US rights for aclidinium from Almirall, while Almirall maintains rights for the rest of the world. The companies are jointly involved in the development of the compound.

Aclidinium bromide is administered to patients using a novel, state-of-the-art multidose dry powder inhaler (MDPI), Genuair(R)(2). Genuair(R) was designed with an intuitive feedback system, which through a 'colored control window' and an audible click indicates that the patient has inhaled correctly. The Genuair(R) inhaler contains multiple doses with a visible dose level indicator and also incorporates significant safety features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information co
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... TRIANGLE PARK, N.C. , July 29, 2014 ... on cloud-based drug design and development, announced today ... grant from the National Science Foundation Small Business ... valued at $150,000. Cloud Pharmaceuticals ... the development process by implementing new, innovative cloud ...
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
(Date:7/29/2014)... 29, 2014   ... it has taken an exclusive worldwide licence to an ... Durham University spin-out company.  Under ... an upfront fee, development and commercial milestone payments, and ... taken an option for additional exclusive licences to FScan ...
Breaking Medicine Technology:Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000 2Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3
... America, Inc. (SAI), a leading medical diagnostic instrument ... Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: ... for Sysmex America, Inc. to provide fully automated ... of the systems has been completed.   ...
... Medical Systems (NYSE: VAR ) will hold an ... of  the American Society for Therapeutic Radiology and Oncology (ASTRO) ... are invited to join senior management for a review of ... at ASTRO. Varian will host a meeting with ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010 2
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
(Date:7/29/2014)... 2014 “Approximately 18% of our population ... common chronic illnesses,” Western Washington Medical Group says in ... for those suffering from allergies to seek medical attention. ... care each year in the United States,” they continue. ... of life for themselves, rather than seeking the appropriate ...
(Date:7/29/2014)... Seattle, WA (PRWEB) July 29, 2014 Award-winning ... PoofPad , a flatulence neutralizer specifically designed to absorb embarrassing ... activated charcoal that can easily be stored in a desk ... To use the PoofPad, users will simply sit on the ... pass gas at the office and then BAM, someone appears ...
(Date:7/29/2014)... 29, 2014 Riverdale Urgent Care is ... do. Through their presence at local events, partnerships and ... more than just a medical service for the Riverdale ... money in support of Riverdale RiverFest and South Riverdale ... that features local musicians and entertainers, arts and crafts, ...
Breaking Medicine News(10 mins):Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3
... recommendations for the diagnosis and subsequent treatment of superior ... the New England Journal of Medicine. ,The ... vena cava syndrome, provides clinical management evidence, and presents ... Lynn D. Wilson, M.D., MPH, Professor, Clinical Director, and ...
... need medical care in Korea but can afford it ... health services, according to a Yale School of ... Health. ,Low-income individuals with multiple chronic ... restrictions because they need and use more services, said ...
... to create therapies or simply investigate how organisms develop, ... of biological science's toughest assignments: keeping their tiny research ... notoriously finicky tastes, and despite a decade of advances, ... cells will continue dividing indefinitely in culture or begin ...
... needed to determine the true effects of low to ... impact on pregnant women of different policies on ... ,Recommendations for safe levels of drinking during ... organisations in Australia, according to new report written by ...
... of yoghurt could contain the cure for certain types ... . ,Overuse of antibiotics has led ... vancomycin-resistant enterococci (VRE), which are responsible for persistent and ... commercial yoghurts, may have a beneficial effect on human ...
... deceased older donors on a pump as opposed to ... cooler may lower hospital costs, improve initial organ ... according to new research by Wake Forest University Baptist Medical ... preservation times can be safely extended to permit more time ...
Cached Medicine News:Health News:Clinical Approach Defined for Superior Vena Cava Syndrome 2Health News:Poor and Chronically Ill in Korea Pay More for Healthcare 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 3Health News:Better Research Needed On Alcohol In Pregnancy 2Health News:Preserving Kidneys on a Pump May Promote More Organ Sharing 2
100L...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: